戻る Agenda
Session 5: What Measures/Metrics Are in Use?
Session Chair(s)
Stella Stergiopoulos, MPH, MS
Director, Health Economic and Outcomes Research, EQRx, United States
The work of early adopters of patient engagement has extended to the development of effectiveness and impact measures of patient involvement during the medical product lifecycle. As theoretical concepts have been translated to practical applications, common metrics have emerged for measuring process implementation as well as quality and impact of engagement. This session will identify commonly used metrics and present case studies of specific applications. Difficult to measure areas will be examined with discussion of suitable metrics that can be developed to assess progress and impact of patient centered efforts.
Learning Objective : At the conclusion of this session, participants should be able to:- Describe examples of effective measurements/metrics currently applied to patient-centered efforts in drug development
- Identify gaps where effective measurements/metrics are not currently available or widely known
- Discuss types of metrics that could be developed to address the gap areas
Speaker(s)
Ellen Coleman, MPH, MS
President and Chief Executive Officer, VOZ Advisors, United States
What Measures/Metrics Are in Use?
Carrie Corboy, PHARMD, RPH
Senior Director, Standards & Execution Excellence, Janssen Global Services, United States
What Measures/Metrics Are in Use?
Nancy Mulligan
Executive Director, Patient & Physician Services, UBC, United States
Speaker
Karlin Schroeder, MA
Associate Vice President, Community Engagement, Parkinson's Foundation, United States
What Measures/Metrics Are in Use?